Six-Year-Old Girl's Sight Restored at Great Ormond Street in 'Life-Changing' Gene Therapy Breakthrough
A six-year-old girl from Hertfordshire has had her sight restored at Great Ormond Street Hospital in London through a pioneering gene therapy treatment, in a story that has brought hope to families across the UK living with rare genetic eye conditions.
Saffie's Story
Saffie Sandford, aged six, from Hertfordshire, was born with Leber's congenital amaurosis (LCA), a rare genetic condition causing retinal dystrophy that severely limits vision, particularly in low light. After receiving Luxturna — an eye gene therapy treatment approved for use on the NHS — at Great Ormond Street Hospital, Saffie's sight has been transformed.
Her mother described the improvement as "life-changing," noting a remarkable difference in Saffie's sight, especially in the dark and in her peripheral vision. The treatment has allowed Saffie to navigate the world in ways that were previously impossible for her.
The Treatment
Luxturna works by delivering a functional copy of the RPE65 gene directly to the retinal cells, allowing them to produce the protein needed for normal vision. The treatment is approved for use on the NHS for patients with LCA caused by mutations in the RPE65 gene, and researchers emphasise the importance of treating children at a young age to improve sight during critical brain development.
Great Ormond Street Hospital is one of the leading centres for paediatric gene therapy in the world, and Saffie's case represents the latest in a series of remarkable outcomes for children with rare genetic conditions treated at the hospital.
Why It Matters
Gene therapy represents one of the most exciting frontiers in modern medicine, offering the potential to treat or cure conditions that were previously considered untreatable. Saffie's story is a powerful reminder of the transformative impact that NHS-funded research and treatment can have on individual lives and families.
What's Next
Researchers at Great Ormond Street are continuing to develop gene therapy treatments for a range of rare genetic conditions. The success of Luxturna in treating LCA is expected to pave the way for further approvals and expanded access to gene therapy on the NHS.
